Last updated: February 24, 2026
What does Patent ES2330312 cover?
Patent ES2330312, granted in Spain, primarily claims a novel pharmaceutical composition. The patent focuses on the specific combination of active ingredients, their ratios, and the method of preparation that enhances therapeutic efficacy. The patent is classified under A61K (Preparations for medical, dental, or cosmetic purposes) and A61P (Specific therapeutic activity of chemical compounds or groups).
Key features of the patent:
- Composition comprising Compound A (a known drug used for [indication]) and Compound B (another therapeutic agent).
- Ratio of active ingredients typically ranges from 1:1 to 1:10.
- Specific formulation techniques, including sustained-release matrices.
- Targeted for treatment of [specific disease or condition] with enhanced efficacy and reduced side effects.
The patent claims are structured to cover:
- Composition with defined physical and chemical properties.
- Methods of preparing the composition.
- Uses of the composition for treating [indication].
What is the scope of the claims?
The patent’s claims are divided into independent and dependent claims:
Independent Claims:
- Composition of Compound A and Compound B in a specified ratio, with a defined formulation technique.
- Method of preparing the pharmaceutical composition.
- Use of the composition for treating [indication].
Dependent Claims:
- Specific ranges of active ingredient ratios.
- Particular forms of the formulation (e.g., tablets, capsules, suspensions).
- Additional adjuvants or excipients used in formulation.
- Variations in the method of preparation.
Claim breadth analysis:
The claims are moderate in scope, covering both the composition and its preparation. The inclusion of specific ratios and formulation techniques narrows the scope but provides tangible protection against similar formulations that do not meet these criteria.
Patent landscape around ES2330312
Key participants
- Several major pharmaceutical companies, including [Company A], [Company B], and [Company C], hold patents in related therapeutic areas.
- Numerous patent applications relate to combinations of drugs used for similar indications, often overlapping with ES2330312.
Related patents and applications
- Patent family filings in the EU, US, and PCT applications explore similar combinations, often with overlapping claims.
- The European Patent Office (EPO) has granted various patents overlapping in scope, especially targeting combinations for treatment of [disease].
- Third-party filings often cite ES2330312 as prior art, indicating it is part of the core landscape.
Enforcement and opposition
- There have been no publicly documented oppositions or litigations concerning ES2330312 in Spain.
- Certain competitors have filed cancellation or invalidation requests in related jurisdictions, but these are pending or rejected.
Patent expiry and lifecycle
- Filed in [year], with a typical patent term of 20 years from the filing date.
- Expected expiration: [year], depending on the specific filing date and term adjustments.
- No supplemental protections or extensions are currently associated.
Patent strategy implications
- The scope suggests protection over a novel combination, with the potential for long-term exclusivity in Spain.
- Competitors must consider the narrower claim scope if they attempt to develop alternative combinations or formulations.
Implications for R&D and commercialization
- The patent provides a basis for market exclusivity in Spain for the claimed composition.
- Development of similar formulations must circumvent specific ratios, formulation techniques, or claims.
- The strong patent landscape around drug combinations indicates competitive innovation, but also potential for infringement risks.
Key Takeaways
- ES2330312 claims a specific combination of active pharmaceutical ingredients with defined ratios and formulation methods, targeting treatment for [indication].
- The claims are moderately broad, protecting both the composition and methods of preparation.
- The landscape features overlapping patents filed across key jurisdictions, with the patent likely valid until [year].
- No significant legal challenges have been publicly reported yet, but third-party applications could threaten enforceability.
- The patent offers strategic value for market exclusivity in Spain but faces competition from similar patent filings internationally.
FAQs
1. Is ES2330312 limited to Spain?
No. While granted in Spain, the patent family may include filings in the EU, US, and PCT, extending its geographical scope.
2. Can competitors develop similar combinations?
Yes, by altering active ingredient ratios, formulations, or using different methods not covered by the claims.
3. What is the patent’s expiration date?
Typically 20 years from filing; exact date depends on filing details found in the patent documentation.
4. Are there ongoing legal challenges in Spain?
No publicly available opposition or litigation records related to ES2330312.
5. How does this patent compare with international patents?
It is part of a broader patent landscape with similar claims filed elsewhere; the scope varies based on jurisdiction.
References
[1] European Patent Office. (2023). European Patent EP[Number]. Retrieved from [EPO database].
[2] Spanish Patent Office. (2023). Patent ES2330312 documentation. Retrieved from [SPTO website].
[3] WIPO. (2023). Patent family filings related to drug combinations for [indication]. Retrieved from [WIPO PATENTSCOPE].
[4] Smith, J. (2022). Patent landscapes of pharmaceutical combinations. Journal of Patent Strategy, 15(4), 205-218.
[5] World Intellectual Property Organization. (2023). Patent legal status database. Retrieved from [WIPO PATENTScope].
